Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study.


Journal

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443

Informations de publication

Date de publication:
04 2019
Historique:
received: 04 07 2018
revised: 06 11 2018
accepted: 07 11 2018
pubmed: 1 1 2019
medline: 10 6 2020
entrez: 1 1 2019
Statut: ppublish

Résumé

Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data. About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users. Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting.

Sections du résumé

BACKGROUND
Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries.
OBJECTIVES
To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App.
METHODS
An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach.
RESULTS
A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data. About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users.
CONCLUSION AND CLINICAL RELEVANCE
Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting.

Identifiants

pubmed: 30597673
doi: 10.1111/cea.13333
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

442-460

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Enrica Menditto (E)

CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy.

Elisio Costa (E)

UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), University of Porto, Porto, Portugal.

Luis Midão (L)

UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), University of Porto, Porto, Portugal.

Sinthia Bosnic-Anticevich (S)

Woolcock Institute of Medical Research, University of Sydney Woolcock Emphysema Centre and Sydney Local Health District, Glebe, New South Wales, Australia.

Ettore Novellino (E)

University of Naples Federico II, Naples, Italy.

Slawomir Bialek (S)

Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland.

Vitalis Briedis (V)

Lithuanian University of Health Sciences, Kaunas, Lithuania.

Alpana Mair (A)

DG for Health and Social Care, Scottish Government, Edinburgh, UK.

Rojin Rajabian-Soderlund (R)

Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden.

Sylvie Arnavielhe (S)

KYomed INNOV, Montpellier, France.

Anna Bedbrook (A)

MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France.

Wienczyslawa Czarlewski (W)

Medical Consulting Czarlewski, Levallois, France.

Isabella Annesi-Maesano (I)

Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France.

Josep M Anto (JM)

ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.
IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Philippe Devillier (P)

Laboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes, France.
Université Versailles Saint-Quentin, Université Paris Saclay, Paris Saclay, France.

Govert De Vries (G)

Peercode BV, Geldermalsen, The Netherlands.

Thomas Keil (T)

Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany.

Aziz Sheikh (A)

The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.

Valentina Orlando (V)

CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy.

Désirée Larenas-Linnemann (D)

Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.

Lorenzo Cecchi (L)

SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.

Giulia De Feo (G)

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.

M Illario (M)

Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy.

Cristiana Stellato (C)

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.

Joao Fonseca (J)

CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
MEDIDA, Lda, Porto, Portugal.

Joao Malva (J)

Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal.
Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal.

Mario Morais-Almeida (M)

Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.

Ana Maria Pereira (AM)

Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal.
Center for Research in Health Technologies and Information Systems CINTESIS, Universidade do Porto, Porto, Portugal.

Ana Maria Todo-Bom (AM)

Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Violeta Kvedariene (V)

Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Arunas Valiulis (A)

Department of Public Health, Clinic of Children's Diseases, and Institute of Health Sciences, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania.
European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.

Karl Christian Bergmann (KC)

Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Department of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany.

Ludger Klimek (L)

Euforea, Brussels, Belgium.

Ralph Mösges (R)

Medical Faculty, Institute of Medical Statistics, and Computational Biology, University of Cologne, Cologne, Germany.
CRI-Clinical Research International-Ltd, Hamburg, Germany.

Oliver Pfaar (O)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany.

Torsten Zuberbier (T)

Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Department of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany.

Vicky Cardona (V)

Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron, & ARADyAL Spanish Research Network, Barcelona, Spain.

Joaquim Mullol (J)

Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain.
Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.

Nikos G Papadopoulos (NG)

Division of Infection, Immunity& Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.
Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou", University of Athens, Athens, Greece.

Emmanuel P Prokopakis (EP)

Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece.

Mike Bewick (M)

iQ4U Consultants Ltd, London, UK.

Dermot Ryan (D)

Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK.

Regina E Roller-Wirnsberger (RE)

Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Peter Valentin Tomazic (PV)

Department of ENT, Medical University of Graz, Graz, Austria.

Alvaro A Cruz (AA)

ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil.
WHO GARD Planning Group, Salvador, Brazil.

Piotr Kuna (P)

Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.

Boleslaw Samolinski (B)

Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.

Wytske J Fokkens (WJ)

Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands.

Sietze Reitsma (S)

Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands.

Isabelle Bosse (I)

Allergist, La Rochelle, France.

Jean-François Fontaine (JF)

Allergist, Reims, France.

Daniel Laune (D)

KYomed INNOV, Montpellier, France.

Tari Haahtela (T)

Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Sanna Toppila-Salmi (S)

Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Claus Bachert (C)

Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.

Peter W Hellings (PW)

Department of Otorhinolaryngology, Univ Hospitals Leuven, Leuven, Belgium.
Academic Medical Center, Univ of Amsterdam, Amsterdam, The Netherlands.
Euforea, Brussels, Belgium.

Erik Melén (E)

Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden.
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Magnus Wickman (M)

Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden.

Carsten Bindslev-Jensen (C)

Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.

Esben Eller (E)

Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.

Robyn E O'Hehir (RE)

Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Department of Immunology, Monash University, Melbourne, Victoria, Australia.

Cemal Cingi (C)

ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.

Bilun Gemicioğlu (B)

Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Omer Kalayci (O)

Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey.

Juan Carlos Ivancevich (JC)

Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.

Jean Bousquet (J)

MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France.
Euforea, Brussels, Belgium.
INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France.
Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH